Play­ing a hot hand in can­cer R&D, Pfiz­er scores its 4th drug ap­proval in just 2 months

Pfiz­er’s hot hand in on­col­o­gy con­tin­ued this week with an FDA OK for glas­deg­ib, an oral drug de­signed to throw a mon­key wrench in­to the bi­ol­o­gy dri­ving the hedge­hog path­way in acute myeloid leukemia.

The drug, Pfiz­er’s fourth on­col­o­gy prod­uct ap­proval in just two months, will now be sold as Dau­ris­mo in com­bi­na­tion with chemo for new­ly di­ag­nosed cas­es of AML, when pa­tients can’t tol­er­ate the kind of in­ten­sive chemo regime need­ed to rein in the blood can­cer. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.